Last reviewed · How we verify
CellREADY® drug product IV dose of 50 millions — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CellREADY® drug product IV dose of 50 millions (CellREADY® drug product IV dose of 50 millions) — University Hospital, Toulouse.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CellREADY® drug product IV dose of 50 millions TARGET | CellREADY® drug product IV dose of 50 millions | University Hospital, Toulouse | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CellREADY® drug product IV dose of 50 millions CI watch — RSS
- CellREADY® drug product IV dose of 50 millions CI watch — Atom
- CellREADY® drug product IV dose of 50 millions CI watch — JSON
- CellREADY® drug product IV dose of 50 millions alone — RSS
Cite this brief
Drug Landscape (2026). CellREADY® drug product IV dose of 50 millions — Competitive Intelligence Brief. https://druglandscape.com/ci/cellready-drug-product-iv-dose-of-50-millions. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab